Belgium· BE-AMP-SAM662252-00
Omjjara 100 mg
A momelotinib product containing momelotinib dihydrochloride monohydrate, registered in Belgium by GlaxoSmithKline Trading Services. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Momelotinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Momelotinib · ATC L01EJ04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of momelotinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Momelotinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$309.44
- FR France$0.16
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Momelotinib Dihydrochloride Monohydrate
- Manufacturer
- GlaxoSmithKline Trading Services
- Country
- Belgium (BE)
- ATC code
- L01EJ04
- ATC class
- Momelotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4791711
- be_apb7743867
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Momelotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandOmjjara 100 mg, FilmtablettenGlaxoSmithKline AG
- CzechiaOMJJARAGlaxoSmithKline Trading Services Limited, Dublin
- SpainOMJJARA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGlaxosmithkline Trading Services Limited
- FinlandOmjjaraGlaxosmithkline Trading Services Limited
- FranceOMJJARA 100 mg, comprimé pelliculéGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- IrelandOmjjara 100 mg film-coated tabletsGlaxoSmithKline Trading Services Limited
- IcelandOmjjaraGlaxoSmithKline Trading Services Limited
- NetherlandsOmjjara 100 mg, filmomhulde tablettenGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omjjara
- Liechtenstein · Omjjara
- Norway · Omjjara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4da0f08d-1828-47b6-b1c0-a4c71d0a377d GET /v1/drugs/4da0f08d-1828-47b6-b1c0-a4c71d0a377d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Omjjara 100 mg",
"name_fr": "Omjjara 100 mg",
"name_nl": "Omjjara 100 mg",
"amp_code": "SAM662252-00",
"strengths": [
"100.0000",
"100.0000",
"50.8000"
],
"pack_count": 1,
"substances": [
"Momelotinib Dihydrochloride Monohydrate",
"Momelotinib",
"Lactose Monohydrate",
"Sodium Starch Glycolate (Type A)"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Momelotinib",
"authorisation_numbers": [
"EU/1/23/1782/001"
]
}See everything about momelotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.